Building a Post-Market Cybersecurity Plan for Your Medical Device

Most manufacturers think about cybersecurity as a premarket requirement — get the device tested, include the report in the submission, get cleared. But the FDA's expectations don't stop at clearance. Section 524B of the FD&C Act requires manufacturers to maintain cybersecurity throughout the device's total product lifecycle.

This means your submission needs a post-market cybersecurity plan, and the FDA will review it. Here's what that plan needs to include and how to build one that doesn't get sent back.

Why Post-Market Cybersecurity Matters

New vulnerabilities are discovered constantly. The OpenSSL library your device uses today might have a critical CVE disclosed next month. The BLE stack you integrated might be found to have a pairing bypass. A researcher might publish an exploit for the RTOS your device runs on.

If your device is on the market and you don't have a plan for addressing these situations, patients are at risk — and the FDA knows it.

What the FDA Expects

The FDA's premarket cybersecurity guidance outlines several post-market expectations:

Coordinated Vulnerability Disclosure (CVD)

You need a documented process for receiving, evaluating, and responding to vulnerability reports from external researchers, customers, and government agencies (like CISA). This includes:

• A publicly accessible way to report vulnerabilities (typically a security contact email or a web form)
• An internal triage process for evaluating reported vulnerabilities
• Defined timelines for acknowledging reports and providing status updates
• A commitment to coordinated disclosure — working with the reporter to fix the issue before public disclosure

If a security researcher finds a vulnerability in your device and can't find a way to report it, that's a problem the FDA takes seriously.

Software Bill of Materials (SBOM) Monitoring

Your premarket submission included an SBOM. Post-market, you need to actively monitor the components in that SBOM for newly disclosed vulnerabilities. When a CVE is published that affects a component in your device, you need a process to:

1. Assess whether the vulnerability is exploitable in your device's configuration
2. Determine the clinical impact if it is exploitable
3. Develop and deploy a patch if needed
4. Communicate with affected customers

This is not optional. The FDA expects evidence that you're monitoring, not just that you created an SBOM once.

Patch Management

You need a defined process for developing, testing, and deploying security patches to devices in the field. Key questions the FDA will ask:

• How quickly can you develop and test a patch for a critical vulnerability?
• How are patches delivered to devices? (Over-the-air, USB, through clinical IT?)
• How do you ensure patches don't break clinical functionality?
• How do you track which devices in the field have been patched?
• What's your process for patches that require regulatory review before deployment?

Security Monitoring and Incident Response

If your device has network connectivity, the FDA expects some level of monitoring capability:

• Can the device detect and log security-relevant events?
• Can clinical IT monitor the device for anomalous behavior?
• Do you have an incident response plan for when a security event is detected?

This doesn't mean your device needs a built-in SIEM. But it does mean you need to think about how security incidents involving your device will be detected and handled.

Building the Plan

Step 1: Define Your Security Contact

Create a public security contact — at minimum, a dedicated email address (e.g., security@yourcompany.com). Better yet, set up a vulnerability disclosure policy (VDP) page on your website that explains:

• How to report a vulnerability
• What information to include
• Your commitment to not pursue legal action against good-faith researchers
• Your timeline for acknowledging and responding to reports

Step 2: Set Up SBOM Monitoring

You don't need to build this from scratch. Several commercial tools monitor SBOMs against CVE databases automatically. The key is making sure:

• Your SBOM is up to date with every firmware release
• Monitoring is continuous, not periodic
• Alerts are triaged by someone who understands the device's architecture and can assess exploitability

Step 3: Define Your Patch Process

Document a clear patch management process:

1. Identification: New vulnerability identified (via SBOM monitoring, researcher report, or internal discovery)
2. Assessment: Determine exploitability in your device's specific configuration and clinical impact
3. Development: Create a patch that addresses the vulnerability without affecting clinical functionality
4. Testing: Verify the patch works and doesn't introduce regressions
5. Deployment: Deliver the patch to devices in the field via your update mechanism
6. Verification: Confirm deployment and track which devices have been updated

Define target timelines for each step. The FDA doesn't prescribe specific timelines, but they expect you to have them — and they should be proportional to the severity of the vulnerability.

Step 4: Plan for Ongoing Testing

Your initial penetration test covers the device at a point in time. As you release firmware updates, add features, and change components, the security posture changes. Plan for ongoing testing:

• Differential testing after significant firmware updates — focused on what changed rather than retesting the entire device
• Annual or semi-annual assessments for devices with long market lifetimes
• Ad-hoc testing when integrating new components or protocols

We support all of these engagement types, including discounted rates for bundled ongoing testing.

Step 5: Document Everything

The FDA wants to see your plan in writing as part of your premarket submission. It doesn't need to be hundreds of pages, but it needs to be specific:

• Who is responsible for each part of the plan
• What tools and processes you use
• What your timelines are
• How you communicate with customers about vulnerabilities and patches

Common Mistakes

Writing a plan you can't actually execute

Don't promise 24-hour patch deployment if your update mechanism requires clinical IT to manually install updates. Be realistic about your capabilities and document them honestly.

Treating the plan as a one-time document

Your post-market cybersecurity plan should be a living document. Update it as your processes improve, as new tools become available, and as you learn from incidents.

Forgetting about end-of-life

What happens when you stop supporting a device? The FDA expects you to communicate end-of-life cybersecurity plans to customers — including recommendations for mitigation when patches are no longer available.

Not testing your incident response

A plan that's never been tested is a plan that won't work when you need it. Run tabletop exercises to identify gaps before a real incident exposes them.

How This Fits Into Your Submission

Your post-market cybersecurity plan is typically a standalone section in your premarket submission, referenced from your cybersecurity documentation. It should:

• Summarize your coordinated vulnerability disclosure process
• Describe your SBOM monitoring approach
• Outline your patch management process with timelines
• Reference any ongoing testing commitments
• Include your security contact information

The FDA reviewers aren't expecting perfection — they're looking for evidence that you've thought about the problem and have a reasonable plan. Manufacturers who include a thoughtful post-market plan in their initial submission are far less likely to receive an ANIN letter asking for one.